Pricing Log in Create free account
Friday 6 November 2026 Export VMD’s income statement to Excel — free account

Viemed Healthcare, Inc.

VMD Healthcare Medical Devices

Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024.

Revenue
+12.2%
EPS
+33.3%
Free cash flow
−67.6%
Total debt
−76.2%

Quarter to September 2026, against a year earlier

9.23 0.22 +2.44%
Market cap
$343.2M
P/E
22.0×
Fwd P/E
23.4×
Dividend yield
—
F-score
5/9
Altman Z
5.58
Beneish M
−3.18
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.59
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 1 — — 2 — — — — —
Insider Ownership 13.97%

Capital & Financial Ratios $m

Size
Market Cap 343.17
Revenue ttm 310.37
Net income ttm 16.17
Free cash flow ttm 26.06
Net debt Q (4.65)
Valuation
P/E 21.98
Forward P/E 23.40
Price / sales 1.11
Forward P/S Powerpack
Price / FCF 13.18
Price / book 2.26
Financial health
Current ratio Q 1.25
Debt / equity Q 0.03 (at or below 0.5: strong)
Interest coverage Q 20.13
Growth
Revenue growth Q +12.18% (above 0%: growing)
Operating income growth Q +13.79% (above 0%: growing)
EPS, this year +11.71%
EPS, next year A +31.45% (at or above 15%: strong)
Revenue, next year A +17.62% (at or above 10%: strong)
EPS, past 5 yrs −13.86% (below 0%: weak)
EPS, next 5 yrs A +23.09% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.1×, against a ten-year median of 1.8×; over the ten years it ranged from 0.9× in 2025 to 4.0× in 2019.
P/E against its own 10 years 29.34%
10-year low 10-year high
P/S against its own 10 years 5.58%
10-year low 10-year high
P/B against its own 10 years 17.30%
10-year low 10-year high
EV/Sales against its own 10 years 7.03%
10-year low 10-year high
EV/FCF against its own 10 years 28.66%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 13 18 14 10
Receivables 18 25 26 —
Inventory 5 4 5 5
Other — — — —
38 53 48 59
2023 2024 2025 Q'26
Payables 4 5 7 11
ST’ Debt 1 0 1 1
Other — — — —
32 37 41 47

Compound Annual Growth %

10y 5y 3y
Sales — 15.53% 24.87%
Cash Flow — 8.14% 23.22%
Earnings — (13.88%) 33.89%
Book Value — 11.93% 13.91%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.10 Actual 0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY23 0.07 0.04 Miss by 0.03
Q4 FY25 0.12 0.14 Beat by 0.02
Q1 FY26 0.09 0.06 Miss by 0.03
Q2 FY26 0.10 0.07 Miss by 0.03
Q3 FY26 0.12 — Reports 4 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.06 0.07 0.11 — —
’25 0.06 0.08 0.09 0.14 0.37
’24 0.04 0.04 0.10 0.10 0.28
’23 0.04 0.06 0.07 0.09 0.25
’22 0.04 0.02 0.03 0.06 0.16
’21 0.04 0.04 0.04 0.10 0.22
’20 0.11 0.48 0.07 0.12 0.78
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 75 78 81 — —
’25 59 63 72 76 270
’24 51 55 58 61 224
’23 40 43 49 51 183
’22 32 33 36 38 139
’21 28 27 29 32 117
’20 24 43 33 31 131
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 8 16 11 — —
’25 3 12 18 18 52
’24 1 10 13 15 39
’23 10 8 14 13 45
’22 7 5 8 8 28
’21 5 4 5 9 22
’20 1 21 7 6 35
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 9 4 — —
’25 (6) 11 12 11 28
’24 (4) 2 8 6 12
’23 7 3 7 6 22
’22 3 (2) 2 2 6
’21 3 1 (3) 2 3
’20 (1) 22 5 1 27
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 31 47 64 80 131 117 139 183 224 270 310 +27.3% 318 354 400 +14.0%
Gross margin, % 75.28 73.76 74.11 69.78 61.01 62.71 60.99 61.63 59.40 57.52 57.41 (17.8) pt
EBT 0 8 10 9 26 13 9 14 16 22 23 +80.5%
EBT margin, % 0.35 17.45 15.00 10.96 20.08 10.68 6.48 7.86 7.21 8.05 7.36 +7.7 pt
Net income 1 8 10 9 32 9 6 10 11 15 16 +32.7%
Per share, $
Per share, $ Revenue 0.81 1.24 1.70 2.13 3.39 2.96 3.59 4.77 5.79 6.95 8.15 +26.9%
Earnings 0.03 0.22 0.27 0.23 0.81 0.23 0.16 0.27 0.29 0.38 0.41 +32.8%
Cash flow 0.17 0.32 0.59 0.51 0.91 0.57 0.72 1.18 1.01 1.33 1.41 +26.1%
Capex 0.00 (0.09) (0.14) (0.34) (0.20) (0.48) (0.56) (0.61) (0.71) (0.61) (0.73) n/m
Free cash flow 0.17 0.22 0.45 0.17 0.71 0.08 0.15 0.57 0.30 0.72 0.68 +17.7%
Book value 0.34 0.63 0.86 1.16 2.11 2.40 2.51 2.97 3.44 3.69 3.99 +30.4%
Shares, m 38 38 38 38 39 39 39 38 39 39 38 +0.3%
Valuation, ×
Valuation, × P/E 1,104,377.10 8.05 14.17 26.36 9.58 22.70 50.33 29.59 27.66 19.05 21.98 110,458.5
P/S 0.00 0.00 2.22 2.91 2.29 1.76 2.10 1.67 1.39 1.07 1.11 1.5
P/B 0.00 0.00 4.44 5.35 3.68 2.17 3.01 2.69 2.33 2.01 2.26 2.6
EV/Sales 0.00 0.00 2.06 2.90 2.12 1.57 1.99 1.64 1.33 1.07 1.09 1.5
EV/FCF 0.00 0.00 7.89 37.11 10.18 54.91 46.61 13.86 25.54 10.25 13.00 20.6
Cash, $m
Cash, $m Operating cash flow 6 12 22 19 35 22 28 45 39 52 54 +26.4%
Capex (2) (4) (5) (13) (8) (19) (22) (24) (27) (24) (28) +34.6%
Free cash flow 6 8 17 6 27 3 6 22 12 28 26 +18.1%
Balance, $m
Balance, $m Working capital 2 4 4 2 24 29 21 6 16 7 12 +15.6%
Net debt 2 0 (7) (1) (23) (22) (16) (6) (14) (1) (5) n/m
Shareholders’ equity 13 24 33 44 82 95 97 114 133 144 152 +30.8%
Returns, %
Returns, % ROA 3.87 26.29 20.82 12.51 32.31 7.92 5.30 7.53 6.79 7.94 7.62 +4.1 pt
ROIC 0.00 23.14 24.86 13.48 21.68 8.97 5.88 8.59 8.44 8.98 0.00 +9.0 pt
ROE 6.59 44.75 33.77 22.35 50.29 10.34 6.48 9.71 9.11 10.79 10.87 +4.2 pt
People
People Employees — — 321 418 511 627 743 996 1,179 1,382 — +23.2%
Revenue/emp, $m 0.00 0.00 0.20 0.19 0.26 0.19 0.19 0.18 0.19 0.20 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Viemed Healthcare, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BWAY Brainsway Ltd. Sponsored ADR $427.1M 21.2× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
SI Shoulder Innovations, Inc. $424.1M — (loss-making) — (loss-making) +37.73% (above 0%: growing) n/m +38.63% (above 0%: growing) 78.47% (46.92%) Compare
RCEL Avita Medical Inc. $389.5M — (loss-making) — (loss-making) +53.05% (above 0%: growing) n/m +86.66% (above 0%: growing) 84.02% (17.95%) Compare
SSII SS Innovations International, Inc. $380.9M — (loss-making) — (loss-making) +39.39% (above 0%: growing) n/m −16.62% (below 0%: shrinking) 50.94% (16.29%) Compare
MOBI Mobia Medical, Inc $375.5M — (loss-making) — (loss-making) +175.85% (above 0%: growing) n/m −18.01% (below 0%: shrinking) 83.25% (118.67%) Compare
OFIX ORTHOFIX MEDICAL INC. $363.3M — (loss-making) — (loss-making) +3.85% (above 0%: growing) n/m −516.58% (below 0%: shrinking) 70.97% (3.86%) Compare
VMD Viemed Healthcare, Inc. $343.2M 22.0× 23.4× +12.18% (above 0%: growing) +33.33% (above 0%: growing) −67.55% (below 0%: shrinking) 57.26% 0.00%
CV CapsoVision, Inc. $329.9M — (loss-making) — (loss-making) +9.89% (above 0%: growing) n/m −84.44% (below 0%: shrinking) 51.36% (208.07%) Compare
CLPT ClearPoint Neuro, Inc. $278.6M — (loss-making) — (loss-making) +36.27% (above 0%: growing) n/m −58.10% (below 0%: shrinking) 58.46% (52.44%) Compare
Median of peers $378.2M — — +37.00% — −34.85% 72.80% (32.43%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 22 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.63m 2.27m 142.34
2024 2.62m 2.51m 153.64
2023 2.51m 2.49m 150.38
2022 1.93m 2.76m 144.83

Ownership

Directors and executive officers, together 20.60%
Casey Hoyt 8.60%
Forager Fund, L.P.2025 7.10%
BlackRock, Inc.50 Hudson YardsNew York, NY 6.60%
Michael Moore 6.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Viemed Healthcare, Inc. (VMD) Latest News

5 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby

4 Nov

Impact 3 · · ACCESS Newswire

22 Oct

Impact 4 · · MarketBeat

29 Aug

Impact 3 · · MarketBeat

11 Aug

Impact 3 · · The Motley Fool transcript

4 Aug

Impact 3 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · Moby transcript

3 Aug

Impact 4 ·
Impact 3 ·

7 May

Impact 3 · · MarketBeat

6 May

Impact 4 · · Moby

5 May

Impact 3 · · Zacks
Impact 3 · · ACCESS Newswire

29 Mar

Impact 3 · · Simply Wall St.

22 Mar

Impact 4 · · MarketBeat

9 Mar

Impact 4 · · GuruFocus.com

6 Mar

Impact 3 · · MarketBeat

5 Mar

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby

4 Mar

Impact 4 · · ACCESS Newswire
Impact 3 · · ACCESS Newswire

6 Feb

Impact 4 · · Simply Wall St.

1 Feb

Impact 4 · · Simply Wall St.

15 Jan

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

6 Jan

Impact 3 · · TMX NewsfileSimply Wall St.BarchartZacksMT NewswiresSimply Wall St.BarchartMT Newswires

30 Dec

Impact 4 · · Simply Wall St.
stockrow.com/VMD · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com